Persons with CKD have significantly higher rates of morbidity, mortality, hospitalizations, and healthcare utilization. Chronic kidney disease may be caused due to comorbid conditions such as high blood pressure, etc. This can lead to buildup of metabolic wastes in patient’s blood and make them feel sick. Chronic kidney disease complications include high blood pressure, anemia (low blood count), weak bones, poor nutritional health, and nerve damage. Chronic kidney disease also increases the risk of developing heart and blood vessel diseases such as heart attack, stroke, etc. These problems may happen slowly over a long period of time.
Market Dynamics
Key players are involved in announcing their results for the clinical trials conducted for the antihypertensive drugs, in order to find the treatment for hypertension in patients suffering from chronic kidney disease. For instance, in 2018, Novartis International AG announced positive results for Entresto (sacubitril/valsartan). According to the clinical trials conducted by the company, it was found that Entresto (sacubitril/valsartan) helped to preserve kidney function in patients suffering from cardiovascular diseases. Moreover, Entresto (sacubitril/valsartan) belongs to angiotensin receptor blockers (ARBs) drug class.
The increasing number of patients undergoing dialysis treatment is expected to drive growth of the global hypertension in CKD market. For instance, according to the data published in the Indian Journal of Public Health (IJPH), in 2018, around 130,000 patients received dialysis treatment in India and the number increased by around 232 patients per million population in India as compared to 2017.
Key features of the study:
- This report provides an in-depth analysis of global hypertension in CKD market , provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global hypertension in CKD market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
- Key companies covered as a part of this study include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global hypertension in CKD market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the hypertension in CKD market
Detailed Segmentation:
- Global Hypertension in CKD Market, By Drug Class:
- Diuretics
- RAS Blockade
- β - Blockers
- Calcium Channel Blockers
- Others
- Global Hypertension in CKD Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Hypertension in CKD Market, By Region:
- North America
- By Drug Class:
- Diuretics
- RAS Blockade
- β - Blockers
- Calcium Channel Blockers
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Drug Class:
- Diuretics
- RAS Blockade
- β - Blockers
- Calcium Channel Blockers
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Class:
- Diuretics
- RAS Blockade
- β - Blockers
- Calcium Channel Blockers
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class:
- Diuretics
- RAS Blockade
- β - Blockers
- Calcium Channel Blockers
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- By Drug Class:
- Diuretics
- RAS Blockade
- β - Blockers
- Calcium Channel Blockers
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class:
- Diuretics
- RAS Blockade
- β - Blockers
- Calcium Channel Blockers
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Sanofi S.A*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- AstraZeneca Plc
- Novartis International AG
- H. Boehringer Sohn AG & Ko. KG
- Kissei Pharmaceutical Co., Ltd.
- Reata Pharmaceuticals, Inc.
- Ardelyx,
- KBP Biosciences Holdings Limited
“*” marked represents similar segmentation in other categories in the respective section.
